--- title: "LP – FCSL Poster 2024: Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens - TD2 Precision Oncology" description: Explore the development and validation of a receptor occupancy assay for a groundbreaking immunotherapy in human whole blood. Learn how flow cytometry-based assays unveil crucial insights into antibody binding, turnover rates, and safety profiles. Dive into the intricacies of antibody-based immunotherapeutics and their potential in treating various diseases. Discover the synergy of immunology and flow cytometry in crafting robust assays for understanding drug-receptor interactions. Uncover the methodology behind our model, integrating fluorophore-labeled drugs, unlabeled counterparts, and non-compete antibodies for comprehensive analysis. image: https://td2inc.com/hubfs/Assets/Images/fcsl-poster-2024-1.png --- ×   [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) # Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens **Authors:** Angela Pell, Carissa Moore, Lynette Brown and Jennifer J Stewart Flow Contract Site Laboratory, 18323 Bothell Everett Highway, Suite 110, Bothell, WA 98012 ![fcsl-poster-2024-1](https://td2inc.com/hs-fs/hubfs/Assets/Images/fcsl-poster-2024-1.png?width=300&name=fcsl-poster-2024-1.png) **Introduction:** Antibody based immunotherapeutics are a growing field of treatment for a variety of disease indications. When conducting safety and efficacy studies, it is important to understand what cells and cell surface receptors your antibody drug is binding to, how long it binds, and the turnover rate of the receptor/drug combination in the patient. Flow cytometry-based receptor occupancy assays on whole blood are the fastest and easiest way to determine this. Developing and validating these assays takes time and knowledge of both immunology and flow cytometry. ### Download Now ## CONTACT US ## Get Started. Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started. [Get Started Now](https://td2inc.com/contact-us/?hsLang=en) [![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/td2-logo.png?width=160&name=td2-logo.png)](https://td2inc.com/?hsLang=en) Office 13208 E. Shea Blvd, Suite 100 Scottsdale, AZ 85259 Phone (602) 358-8300 Connect with us - - ![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/Assets/Logo/acclac-logo.png?width=139&name=acclac-logo.png) © 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)